Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) and Encourages Bellicum Investors to Contact the Firm
May 31, 2019 19:00 ET
|
Bragar Eagel & Squire
NEW YORK, May 31, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM). ...
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 31, 2019 16:14 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, May 31, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals to Present Updated Results for BPX-601 at the 2019 ASCO Annual Meeting
May 15, 2019 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, May 15, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc.
February 12, 2018 15:17 ET
|
Federman & Sherwood
OKLAHOMA CITY, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Federman & Sherwood announces that on February 6, 2018, a class action lawsuit was filed in the United States District Court for the Southern...
Bellicum Reports Clinical Results of BPX-501 in Pediatric Leukemias at the 22nd Congress of the European Hematology Association
June 23, 2017 07:00 ET
|
Bellicum Pharmaceuticals
MADRID, Spain, June 23, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited...
Bellicum Announces Clinical Data on BPX-501 at Presidential Symposium of the 22nd Congress of the European Hematology Association
June 23, 2017 07:00 ET
|
Bellicum Pharmaceuticals
MADRID, Spain, June 23, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited...